Atara Biotherapeutics, Inc.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$2M
↓-95.1% -$31Mvs FY2024 (Q4)
Gross Profit
$2M
↓-95.1% -$31Mvs FY2024 (Q4)
Operating Income
$703K
↓-71.2% -$2Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $2M | $33M |
| COGS | $0 | $0 |
| Gross Profit | $2M | $33M |
| R&D | $0 | $29M |
| SG&A | $0 | $0 |
| D&A | $49K | $1M |
| Other OpEx | $843K | $490K |
| Operating Income | $703K | $2M |
| Interest Exp. | $703K | $1M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $0 | $1M |
| Tax | $0 | $0 |
| Net Income | $0 | $1M |
QuarterCharts · SEC EDGAR data · ATRA · Comparing FY2025 (Q4) vs FY2024 (Q4)